Bayer Doubles Estimate of Baycol-Linked Deaths
Bayer said the number of deaths linked to its cholesterol drug Baycol, withdrawn from sale last year, had doubled from an earlier estimate of 52.
The news sent shares in Germany’s largest drug group down more than 2% less than a week before it makes its debut on the New York Stock Exchange and as it seeks partners for its ailing drug unit.
It revived concerns about the possibility of a hefty compensation payout, already worrying investors after Dow Chemical Co. settled an asbestos lawsuit this month.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
